A Phase III, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Jacobo Hincapie-Echeverri, MD

Phase: III

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07585266

Objective

To evaluate the efficacy (clinical activity) of velzatinib compared with imatinib in previously untreated participants with metastatic and/or unresectable GIST, as evidenced by PFS

Share: